The correlation and relationship of obesity and cancer: A possible research perspective

Chinese-German Journal of Clinical Oncology

Volumn 12, Issue 8, 2013, Pages 393-398

  Sheng, Chunjun ^a   Li, Ruoxue ^b   Yang, Peng ^a   Qu, Shen ^a   Cui, Zheng ^c   Lu, Kun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; correlation; obesity; relationship

Indexed keywords

ADIPOCYTOKINE; ANDROGEN; EPIDERMAL GROWTH FACTOR; ESTROGEN; FATTY ACID SYNTHASE; GLUTAMINE; HYPOXIA INDUCIBLE FACTOR 1; INSULIN; INTERLEUKIN 6; LEPTIN; MYC PROTEIN; PROGESTERONE; PROTEIN KINASE B; PYRUVATE KINASE; SOMATOMEDIN C; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BARRETT ESOPHAGUS; BODY MASS; BREAST TUMOR; BROWN ADIPOSE TISSUE; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; CORRELATIONAL STUDY; ENDOMETRIUM CANCER; ESOPHAGEAL ADENOCARCINOMA; FATTY ACID SYNTHESIS; GASTROINTESTINAL TUMOR; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOXIA; OBESITY; ONCOGENE; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR; WHITE ADIPOSE TISSUE;

EID: 84890415697     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-012-1076-8     Document Type: Article

References (50)

1. World Health Organisation. Fact Sheet No. 311. Obesity and Overweight. 2012. WHO Media centre.
2. World Health Organization. Global prevalence of obesity. 2012. Available at: https://apps.who.int/infobase/Comparisons.aspx.
3. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New Eng J Med, 2003, 348: 1625-1638.
4. Calle EC, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer, 2004, 4: 579-591.
5. Williams G, Frühbeck G. Obesity: Science to practice, Chapter 13. John Wiley & Sons, Ltd Press. 1st edition, 2009. 322-331.
6. Giovannucci E, Michaud D. The role of obe-sity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology, 2007, 132: 2208-2225.
7. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care, 2002, 25: 2244-2248.
8. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol, 2007, 17: 2-9.
9. Skibola CF. Obesity, diet and risk of non-Hodgkin lymphoma. Cancer Epidemiol, Biomarkers & Prev, 2007, 16: 392-395.
10. Schatzl G, Madersbacher S, Thurridl T. High-grade prostate cancer is associated with low serum testosterone levels. Prostate, 2001, 47: 52-58.
11. Carmichael AR. Obesity as a risk factor for development and poor prognosis of breast cancer. Bri J Obst Gyn, 2006, 113: 1160-1166.
12. Modesitt SC, Nagell JR, Jr. The impact of obesity on the incidence and treatment of gyneco-logic cancers: a review. Obst & Gyn Surv, 2005, 60: 683-692.
13. Schäffler A, Schölmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab, 2007, 3: 345-354.
14. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol, Biomarkers & Prev, 2002, 11: 1531-1543.
15. Renehan AG, Tyson M, Egger M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 2008, 371: 569-578.
16. Roberts DL, Dive C, Renehan AG. 2010. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med, 2010, 61: 301-316.
17. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev, 1994, 3: 687-695.
18. Giovannucci E. Insulin and colon cancer. Cancer Causes Control, 1995, 6: 164-179.
19. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett, 2003, 195: 127-137.
20. Desbois-Mouthon C, Cadoret A. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene, 2001, 20: 252-259.
21. Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue - an update. Horm Metab Res, 2007, 39: 314-321.
22. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer, 2007, 14: 189-206.
23. Miyoshi Y, Funahashi T, Kihara S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res, 2003, 9: 5699-5704.
24. Goktas S, Yilmaz MI, Caglar K. Prostate cancer and adiponectin. Urology, 2005, 65: 1168-1172.
25. Hausman DB, DiGirolama M, Bartness TJ. Obesity Rev, 2001, 2: 239-254.
26. Haslam DW, James WP. Obesity. Lancet, 2005, 366: 1197-1209.
27. De Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem, 2008, 54: 945-955.
28. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer, 2007, 7: 763-777.
29. Kuhajda FK. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res, 2006, 66: 5977-5980.
30. Pizer ES, Thupari J, Han WF. Malonyl coenzyme A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res, 2000, 60: 213-218.
31. Zhou W, Simpson PJ, McFadden JM. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res, 2003, 63: 7330-7337.
32. Menendez JA, Vellon L, Mehmi I. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci, 2004, 101: 10715-10720.
33. Wang HQ, Altomare DA, Skele KL. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene, 2005, 24: 3574-3582.
34. Yang YA, Han WF, Morin PJ. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res, 2002, 279: 80-90.
35. Aadra PB, Sarah RJ, Alex J. Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc Natl Acad Sci, 2012, 109: 11818-11823.
36. Wang HQ, Altomare DA, Skele KL. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene, 2005, 24: 3574-3582.
37. Elstrom RL, Bauer DE, Buzzai M. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 2004, 64: 3892-3899.
38. Warburg O. On the origin of cancer cells. Science, 1956, 123: 309-314.
39. Mazurek S, Boschek CB, Hugo F, et al. Pyruvatekinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol, 2005, 15: 300-308.
40. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A, 2007, 104: 19345-19350.
41. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem, 1979, 254: 2669-2676.
42. Elgadi KM, Meguid RA, Qian M, et al. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics, 1999, 1: 51-62.
43. Messina JL. Inhibition and stimulation of c-myc gene transcription by insulin in rat hepatoma cells. Insulin alters the intragenic pausing of c-myc transcription. J Biol Chem, 1991, 266: 17995-8001.
44. Chen C, Chang YC, Liu CL, et al. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat, 2006, 98: 121-132.
45. David CJ, Chen M, Assanah M, et al. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature, 2010, 463: 364-368.
46. Hu S, Balakrishnan A, Bok RA, et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab, 2011, 14: 131-142.
47. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism. Nature, 2009, 458: 762-765.
48. Deberardinis RJ, Sayed N, Ditsworth D, et al. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev, 2008, 18: 54-61.
49. Cao IG, Song MS, Hobbs RM, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell, 2012, 149: 49-62.
50. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 2007, 11: 37-51.